Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.43 |
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656088 | 0.92 | ESR1 (0.41) | THRBESR1EGLN2EGLN1THRA | |
| SCHEMBL1658692 | 0.92 | EGLN1 (0.48) | THRBESR1EGLN2EGLN1THRA | |
| SCHEMBL1656929 | 0.90 | THRB (0.42) | THRBESR1EGLN2EGLN1CNR1 | |
| SCHEMBL522807 | 0.88 | EGLN2 (0.46) | THRBESR1EGLN2EGLN1THRA | |
| SCHEMBL1655981 | 0.87 | EGLN2 (0.55) | EGLN2EGLN1 | |
| SCHEMBL1658846 | 0.86 | EGLN1 (0.43) | THRBESR1EGLN2EGLN1THRA | |
| SCHEMBL15268977 | 0.84 | EGLN1 (0.47) | THRBESR1EGLN2EGLN1THRA | |
| SCHEMBL524033 | 0.84 | EGLN1 (0.49) | THRBESR1EGLN2EGLN1THRA | |
| SCHEMBL523264 | 0.84 | EGLN1 (0.50) | THRBEGLN2EGLN1THRA | |
| SCHEMBL1656684 | 0.83 | SLC2A1 (0.47) | ESR1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2016-01-14 | — | — | US | disclosed |
| US-9174976-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8759373-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2476669-A1 | Cyanoisoquinoline compounds and methods of use thereof | Fibrogen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2044028-B1 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110212959-A1 | Cyanoisoquinoline Compounds and Methods of Use Thereof | FIBROGEN, INC. | 2011-09-01 | — | — | US | disclosed |
| US-7928120-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2044028-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007090068-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | THRB 2538/4885ESR1 1801/4885EGLN2 4/4885 |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | THRB 3066/4885ESR1 2381/4885EGLN2 4/4885 |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | THRB 3066/4885ESR1 2381/4885EGLN2 4/4885 |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | THRB 3066/4885ESR1 2381/4885EGLN2 4/4885 |
| US-20110212959-A1 | Cyanoisoquinoline Compounds and Methods of Use Thereof | HIF1AN, HIF1A, EGLN3 | THRB 3066/4885ESR1 2381/4885EGLN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.